We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
8.00 | 2.63% | 312.00 | 301.00 | 310.00 | 312.00 | 312.00 | 312.00 | 659 | 09:04:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
TIDMHCM
RNS Number : 6331N
Hutchison China Meditech Limited
10 August 2017
Director's Share Dealing
London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) at an average price of US$26.18 per ADS on August 7 and 9, 2017.
Following the above purchases, Ms Shih is interested in 85,663 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated ----- --------------------------------------------------------------------------------------------------------------- a) Name Ms Edith Shih ----- ------------------------------------ ------------------------------------------------------------------------- 2 Reason for the notification ----- --------------------------------------------------------------------------------------------------------------- a) Position/status Non-executive Director and Company Secretary ----- ------------------------------------ ------------------------------------------------------------------------- b) Initial notification/Amendment Initial notification ----- ------------------------------------ ------------------------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----- --------------------------------------------------------------------------------------------------------------- a) Name Hutchison China MediTech Limited ----- ------------------------------------ ------------------------------------------------------------------------- b) LEI 2138006X34YDQ6OBYE79 ----- ------------------------------------ ------------------------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- --------------------------------------------------------------------------------------------------------------- a) Description of the financial ADS each representing one half of one Ordinary Share of US$1.00 instrument, type of instrument ADS ISIN: US44842L1035 Identification code ----- ------------------------------------ ------------------------------------------------------------------------- b) Nature of the transaction Acquisition of 1,807 ADSs on August 7 and 9, 2017 at an average price of US$26.18 per ADS. ----- ------------------------------------ ------------------------------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ----- ------------------------------------ ------------------------------------ ----------------------------------- US$26.10 870 ------------------------------------------------------------------------------- ----------------------------------- US$26.09 200 ------------------------------------------------------------------------------- ----------------------------------- US$25.98 130 ------------------------------------------------------------------------------- ----------------------------------- US$26.30 107 ------------------------------------------------------------------------------- ----------------------------------- US$26.40 100 ------------------------------------------------------------------------------- ----------------------------------- US$26.39 200 ------------------------------------------------------------------------------- ----------------------------------- US$26.38 200 ------------------------------------------------------------------------------- ----------------------------------- d) Aggregated information Aggregated volume: 1,807 ADSs - Aggregated volume Price information: US$26.18 - Price ----- ------------------------------------ ------------------------------------------------------------------------- e) Date of the transaction 2017-08-07 - acquisition of 1,200 ADSs 2017-08-09 - acquisition of 607 ADSs ----- ------------------------------------ ------------------------------------------------------------------------- f) Place of the transaction Nasdaq Stock Market ----- ------------------------------------ -------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries Mark Lee, SVP Corporate Finance & Development +852 2121 8200 U.K. & International Media Enquiries Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFFTTSIILID
(END) Dow Jones Newswires
August 10, 2017 04:35 ET (08:35 GMT)
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions